

Ingrid De Meester

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4033695/publications.pdf>

Version: 2024-02-01

192
papers

10,002
citations

36271

51
h-index

40954

93
g-index

192
all docs

192
docs citations

192
times ranked

9624
citing authors

#	ARTICLE	IF	CITATIONS
1	Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?. <i>Cancers</i> , 2022, 14, 624.	1.7	10
2	Activation of the Carboxypeptidase U (CPU, TAF1a, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1494.	1.0	2
3	Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients. <i>Clinica Chimica Acta</i> , 2022, 531, 4-11.	0.5	8
4	The Effect of Serine Protease Inhibitors on Visceral Pain in Different Rodent Models With an Intestinal Insult. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	4
5	Vildagliptinâ€Derived Dipeptidyl Peptidase 9 (DPP9) Inhibitors: Identification of a DPP8/9â€Specific Lead. <i>ChemMedChem</i> , 2022, 17, .	1.6	8
6	In Vitro and In Situ Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes. <i>Frontiers in Chemistry</i> , 2021, 9, 640566.	1.8	6
7	Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats. <i>Pharmaceutics</i> , 2021, 13, 811.	2.0	10
8	Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAF1a, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study. <i>Clinical Therapeutics</i> , 2021, 43, 908-916.	1.1	4
9	Prolyl Carboxypeptidase Mediates the C-Terminal Cleavage of (Pyr)-Apelin-13 in Human Umbilical Vein and Aortic Endothelial Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6698.	1.8	4
10	In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi. <i>Molecules</i> , 2021, 26, 3482.	1.7	12
11	The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 682065.	1.6	5
12	Use of Nonspecific Protease Inhibitors in Research. <i>Journal of the American College of Cardiology</i> , 2021, 78, 542-543.	1.2	2
13	The C-terminal cleavage of angiotensin II and III is mediated by prolyl carboxypeptidase in human umbilical vein and aortic endothelial cells. <i>Biochemical Pharmacology</i> , 2021, 192, 114738.	2.0	6
14	The Chemokine-Based Peptide, CXCL9(74-103), Inhibits Angiogenesis by Blocking Heparan Sulfate Proteoglycan-Mediated Signaling of Multiple Endothelial Growth Factors. <i>Cancers</i> , 2021, 13, 5090.	1.7	12
15	Proteolytic Cleavage of Bioactive Peptides and Protease-Activated Receptors in Acute and Post-Colitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10711.	1.8	6
16	Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 476-491.	1.0	1
17	Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, e65-e77.	1.1	14
18	A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation. <i>Scientific Reports</i> , 2020, 10, 17268.	1.6	16

#	ARTICLE	IF	CITATIONS
19	Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 19.	1.8	61
20	Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2). <i>PLoS ONE</i> , 2020, 15, e0231555.	1.1	8
21	Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2). , 2020, 15, e0231555.		0
22	Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2). , 2020, 15, e0231555.		0
23	Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2). , 2020, 15, e0231555.		0
24	Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2). , 2020, 15, e0231555.		0
25	Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP). <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1173-1179.	1.3	25
26	Selective Activity-Based Probes Targeting Fibroblast Activation Protein (FAP). <i>Proceedings (mdpi)</i> , 2019, 22, 84.	0.2	0
27	The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity. <i>Carcinogenesis</i> , 2019, 40, 324-334.	1.3	32
28	The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma. <i>Clinica Chimica Acta</i> , 2019, 495, 154-160.	0.5	11
29	CD26/DPP4 - a potential biomarker and target for cancer therapy. , 2019, 198, 135-159.		96
30	DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophages. <i>Life Science Alliance</i> , 2019, 2, e201900313.	1.3	47
31	Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 982-991.	1.2	27
32	DPPIV/CD26 as a Target in Anti-inflammatory Therapy. , 2018, , 133-147.		1
33	Peroxynitrite Exposure of CXCL12 Impairs Monocyte, Lymphocyte and Endothelial Cell Chemotaxis, Lymphocyte Extravasation in vivo and Anti-HIV-1 Activity. <i>Frontiers in Immunology</i> , 2018, 9, 1933.	2.2	5
34	Prolyl carboxypeptidase activity in the circulation and its correlation with body weight and adipose tissue in lean and obese subjects. <i>PLoS ONE</i> , 2018, 13, e0197603.	1.1	18
35	Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome. <i>British Journal of Pharmacology</i> , 2018, 175, 3516-3533.	2.7	33
36	Post-Inflammatory Visceral Hypersensitivity: An Important Role for Serine Proteases and in Particular Tryptase. <i>Gastroenterology</i> , 2017, 152, S211.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Anti-inflammatory effects on ischemia/reperfusion-injured lung transplants by the cluster of differentiation 26/dipeptidylpeptidase 4 (CD26/DPP4) inhibitor vildagliptin. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 713-724.e4.	0.4	15
38	Crystal structure of <i>Porphyromonas gingivalis</i> dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 482-491.	2.6	16
39	Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and <sc>SP</sc>142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. <i>Histopathology</i> , 2017, 70, 253-263.	1.6	37
40	Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity. <i>Translational Stroke Research</i> , 2017, 8, 157-164.	2.3	15
41	Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1513.	1.8	28
42	Regulation of intestinal permeability: The role of proteases. <i>World Journal of Gastroenterology</i> , 2017, 23, 2106.	1.4	124
43	The expression of proline-specific enzymes in the human lung. <i>Annals of Translational Medicine</i> , 2017, 5, 130-130.	0.7	17
44	Epitope mapping of PD-L1 primary antibodies (28-8, SP142, SP263, E1L3N).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3028-3028.	0.8	12
45	Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21030-e21030.	0.8	0
46	Biotransformation of three phosphate flame retardants and plasticizers in primary human hepatocytes: untargeted metabolite screening and quantitative assessment. <i>Journal of Applied Toxicology</i> , 2016, 36, 1401-1408.	1.4	32
47	Prolyl carboxypeptidase purified from human placenta: its characterization and identification as an apelin-cleaving enzyme. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2016, 1864, 1481-1488.	1.1	19
48	Dysregulation of the renin-angiotensin system during lung ischemia-reperfusion injury. <i>Experimental Lung Research</i> , 2016, 42, 277-285.	0.5	5
49	Su1937 Two Serine Protease Inhibitors, Nafamostat Mesylate and the Newly Developed SP1x, Decrease Post-Inflammatory Visceral Hypersensitivity in Rats. <i>Gastroenterology</i> , 2016, 150, S593-S594.	0.6	4
50	Optimization and validation of an existing, surgical and robust dry eye rat model for the evaluation of therapeutic compounds. <i>Experimental Eye Research</i> , 2016, 146, 172-178.	1.2	15
51	CD26 costimulatory blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 508-517.	0.3	35
52	Probing for improved selectivity with dipeptide-derived inhibitors of dipeptidyl peptidases 8 and 9: the impact of P1-variation. <i>MedChemComm</i> , 2016, 7, 433-438.	3.5	11
53	The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice. <i>Inflammation</i> , 2016, 39, 413-424.	1.7	36
54	Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. <i>World Journal of Gastroenterology</i> , 2016, 22, 10275.	1.4	37

#	ARTICLE	IF	CITATIONS
55	Quantification of Vaccine-induced Antipertussis Toxin Secretory IgA Antibodies in Breast Milk. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e149-e152.	1.1	39
56	The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis. <i>Frontiers in Immunology</i> , 2015, 6, 387.	2.2	147
57	Prolyl Carboxypeptidase Activity Decline Correlates with Severity and Short-Term Outcome in Acute Ischemic Stroke. <i>Neurochemical Research</i> , 2015, 40, 81-88.	1.6	11
58	Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 677-687.	1.7	57
59	Potential impact of sitagliptin on collagen-derived dipeptides in diabetic osteoporosis. <i>Pharmacological Research</i> , 2015, 100, 336-340.	3.1	12
60	Circulating Stromal Cell-Derived Factor 1 \pm Levels in Heart Failure: A Matter of Proper Sampling. <i>PLoS ONE</i> , 2015, 10, e0141408.	1.1	15
61	Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold. <i>MedChemComm</i> , 2014, 5, 1700-1707.	3.5	16
62	Breastfeeding after maternal immunisation during pregnancy: Providing immunological protection to the newborn: A review. <i>Vaccine</i> , 2014, 32, 1786-1792.	1.7	78
63	Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. <i>Cardiovascular Research</i> , 2014, 104, 423-431.	1.8	70
64	DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 307, E447-E455.	1.8	58
65	Importance of biofilm formation and dipeptidyl peptidase IV for the pathogenicity of clinical <i>Porphyromonas gingivalis</i> isolates. <i>Pathogens and Disease</i> , 2014, 70, 408-413.	0.8	20
66	Extended Structure-Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3053-3074.	2.9	169
67	Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. <i>Basic Research in Cardiology</i> , 2013, 108, 350.	2.5	71
68	Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 456-468.	2.6	18
69	Dipeptidyl-Peptidase II. , 2013, , 3432-3438.		0
70	Dipeptidyl-peptidase 9. , 2013, , 3384-3389.		0
71	Validation of a specific prolylcarboxypeptidase activity assay and its suitability for plasma and serum measurements. <i>Analytical Biochemistry</i> , 2013, 443, 232-239.	1.1	13
72	Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 491-496.	1.3	153

#	ARTICLE	IF	CITATIONS
73	Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 14-21.	2.9	93
74	CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 41, 1166-1173.	0.6	63
75	P2-Substituted <i>N</i> -Acylprolylpyrrolidine Inhibitors of Prolyl Oligopeptidase: Biochemical Evaluation, Binding Mode Determination, and Assessment in a Cellular Model of Synucleinopathy. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9856-9867.	2.9	24
76	DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, F681-F688.	1.3	86
77	Possible mechanisms for brain natriuretic peptide resistance in heart failure with a focus on interspecies differences and canine BNP biology. <i>Veterinary Journal</i> , 2012, 194, 34-39.	0.6	13
78	The effect of prolyl oligopeptidase inhibition on extracellular acetylcholine and dopamine levels in the rat striatum. <i>Neurochemistry International</i> , 2012, 60, 301-309.	1.9	26
79	DPP4 inhibition alters the pathophysiology of osteoporosis. <i>Bone</i> , 2012, 50, S140.	1.4	0
80	Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. <i>Clinica Chimica Acta</i> , 2012, 413, 456-462.	0.5	71
81	Dipeptidyl Peptidase IV-Activated Prodrugs of Anti-Varicella Zoster Virus Bicyclic Nucleoside Analogues Containing Different Self-Cleavage Spacer Systems. <i>ChemMedChem</i> , 2012, 7, 1612-1622.	1.6	2
82	Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. , 2012, 136, 267-282.		53
83	Dipeptidyl peptidase IV (DPP-IV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning. <i>Experimental Hematology</i> , 2012, 40, 97-106.	0.2	8
84	Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3412-3417.	1.0	39
85	Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. <i>Biological Chemistry</i> , 2011, 392, 189-98.	1.2	66
86	Dipeptidyl Peptidase IV Dependent Water-Soluble Prodrugs of Highly Lipophilic Bicyclic Nucleoside Analogues. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1927-1942.	2.9	14
87	Structure-Activity Relationship Studies on Isoindoline Inhibitors of Dipeptidyl Peptidases 8 and 9 (DPP8, DPP9): Is DPP8-Selectivity an Attainable Goal?. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5737-5746.	2.9	51
88	Soluble CD26-Dipeptidyl Peptidase IV Enhances Human Lymphocyte Proliferation <i>In Vitro</i> Independent of Dipeptidyl Peptidase Enzyme Activity and Adenosine Deaminase Binding. <i>Scandinavian Journal of Immunology</i> , 2011, 73, 102-111.	1.3	54
89	Dipeptidyl peptidase 9 (DPP9) from bovine testes: Identification and characterization as the short form by mass spectrometry. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2010, 1804, 781-788.	1.1	20
90	Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: The pivotal role of vasoactive intestinal peptide. <i>Peptides</i> , 2010, 31, 585-591.	1.2	41

#	ARTICLE	IF	CITATIONS
91	Application of the Dipeptidyl Peptidase IV (DPPIV/CD26) Based Prodrug Approach to Different Amine-Containing Drugs. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 559-572.	2.9	14
92	Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 245-7.	1.4	12
93	A CD26-Controlled Cell Surface Cascade for Regulation of T Cell Motility and Chemokine Signals. <i>Journal of Immunology</i> , 2009, 183, 3616-3624.	0.4	39
94	Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 248-52.	1.4	55
95	Kinetic Study of Neuropeptide Y (NPY) Proteolysis in Blood and Identification of NPY3â€³35. <i>Journal of Biological Chemistry</i> , 2009, 284, 24715-24724.	1.6	60
96	Enzyme Activity and Immunohistochemical Localization of Dipeptidyl Peptidase 8 and 9 in Male Reproductive Tissues. <i>Journal of Histochemistry and Cytochemistry</i> , 2009, 57, 531-541.	1.3	44
97	In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma. <i>Biochemical Pharmacology</i> , 2009, 77, 228-237.	2.0	27
98	Primary Graft Dysfunction in Lung Transplantation: The Role of CD26/Dipeptidylpeptidase IV and Vasoactive Intestinal Peptide. <i>Transplantation</i> , 2009, 87, 1140-1146.	0.5	18
99	The Effect of Organ-Specific CD26/DPP IV Enzymatic Activity Inhibitor-Preconditioning on Acute Pulmonary Allograft Rejection. <i>Transplantation</i> , 2009, 88, 478-485.	0.5	8
100	Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: Isoindoline containing inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4159-4162.	1.0	65
101	Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: Identification of dipeptide derived leads. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4154-4158.	1.0	27
102	DPP4 inhibitors for diabetesâ€”What next?. <i>Biochemical Pharmacology</i> , 2008, 76, 1637-1643.	2.0	55
103	Purification and characterization of dipeptidyl peptidase IV-like enzymes from bovine testes. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 3558.	3.0	22
104	Dipeptidyl peptidase 8/9-like activity in human leukocytes. <i>Journal of Leukocyte Biology</i> , 2007, 81, 1252-1257.	1.5	63
105	Dipeptidyl peptidase II (DPPII), a review. <i>Clinica Chimica Acta</i> , 2007, 380, 31-49.	0.5	69
106	Intragraft DPP IV Inhibition Attenuates Post-transplant Pulmonary Ischemia/Reperfusion Injury After Extended Ischemia. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 174-180.	0.3	33
107	Irreversible Inhibition of Dipeptidyl Peptidase 8 by Dipeptide-Derived Diaryl Phosphonates. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5568-5570.	2.9	51
108	Design and Discovery of a Novel Dipeptidyl-peptidase IV (CD26)-Based Prodrug Approach. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5339-5351.	2.9	26

#	ARTICLE	IF	CITATIONS
109	CD26/Dipeptidylpeptidase IV-targeted Therapy of Acute Lung Rejection in Rats. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 1109-1116.	0.3	21
110	Ischemia/Reperfusion Injury: The Role of CD26/Dipeptidyl-Peptidase-IV-Inhibition in Lung Transplantation. <i>Transplantation Proceedings</i> , 2006, 38, 3369-3371.	0.3	17
111	Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4777-4779.	1.0	7
112	Dipeptidyl peptidase II and leukocyte cell death. <i>Biochemical Pharmacology</i> , 2006, 72, 70-79.	2.0	21
113	Dipeptidyl-Peptidase IV Converts Intact B-Type Natriuretic Peptide into Its des-SerPro Form. <i>Clinical Chemistry</i> , 2006, 52, 82-87.	1.5	178
114	Peptide Substrates of Dipeptidyl Peptidases. <i>Advances in Experimental Medicine and Biology</i> , 2006, 575, 3-18.	0.8	25
115	In Vivo Effects of a Potent, Selective Dppii Inhibitor. <i>Advances in Experimental Medicine and Biology</i> , 2006, 575, 73-85.	0.8	5
116	The Role of CD26/DPP IV in Preservation of Early Pulmonary Graft Function. <i>Advances in Experimental Medicine and Biology</i> , 2006, 575, 231-235.	0.8	0
117	Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). <i>Biochemical Journal</i> , 2005, 386, 315-324.	1.7	67
118	Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). <i>Biochemical Pharmacology</i> , 2005, 70, 134-143.	2.0	113
119	Search for substrates for prolyl oligopeptidase in porcine brain. <i>Peptides</i> , 2005, 26, 2536-2546.	1.2	36
120	Fluoro-Olefins as Peptidomimetic Inhibitors of Dipeptidyl Peptidases. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1768-1780.	2.9	136
121	Exploration of the Active Site of Dipeptidyl Peptidase IV From <i>Porphyromonas gingivalis</i> . <i>Advances in Experimental Medicine and Biology</i> , 2004, 524, 29-35.	0.8	4
122	CD26/DPP IV in Experimental and Clinical Organ Transplantation. <i>Advances in Experimental Medicine and Biology</i> , 2004, 524, 133-143.	0.8	15
123	Dipeptidyl Peptidase IV Substrates. <i>Advances in Experimental Medicine and Biology</i> , 2004, 524, 3-17.	0.8	75
124	Levels and profiles of PCBs and OCPs in marine benthic species from the Belgian North Sea and the Western Scheldt Estuary. <i>Marine Pollution Bulletin</i> , 2004, 49, 393-404.	2.3	105
125	Expression, purification and preliminary crystallographic analysis of dipeptidyl peptidase IV from <i>Porphyromonas gingivalis</i> . <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2004, 60, 1871-1873.	2.5	7
126	$\hat{3}$ -Amino-Substituted Analogues of 1-[(S)-2,4-Diaminobutanoyl]piperidine as Highly Potent and Selective Dipeptidyl Peptidase II Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2906-2916.	2.9	40

#	ARTICLE	IF	CITATIONS
127	Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2003, 40, 209-294.	2.7	793
128	Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors.. <i>ChemInform</i> , 2003, 34, no.	0.1	0
129	Rapid Parallel Synthesis of Dipeptide Diphenyl Phosphonate Esters as Inhibitors of Dipeptidyl Peptidases. <i>ACS Combinatorial Science</i> , 2003, 5, 336-344.	3.3	44
130	Design, Synthesis, and SAR of Potent and Selective Dipeptide-Derived Inhibitors for Dipeptidyl Peptidases. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5005-5014.	2.9	38
131	Natural Substrates of Dipeptidyl Peptidase IV. <i>Advances in Experimental Medicine and Biology</i> , 2002, 477, 67-87.	0.8	71
132	Corrigendum to: Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion (FEBS 25376). <i>FEBS Letters</i> , 2002, 512, 353-353.	1.3	0
133	CD26 expression and enzymatic activity in recipients of kidney allografts. <i>Transplantation Proceedings</i> , 2002, 34, 1753-1754.	0.3	13
134	A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro. <i>Biochemical Pharmacology</i> , 2002, 64, 1753-1756.	2.0	29
135	Development of potent and selective dipeptidyl peptidase II inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2825-2828.	1.0	37
136	DPIV " Natural Substrates of Medical Importance. , 2002, , 223-257.		9
137	Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. <i>FEBS Letters</i> , 2001, 507, 327-330.	1.3	102
138	Ecto-peptidases in pathophysiology. <i>BioEssays</i> , 2001, 23, 251-260.	1.2	64
139	Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family. <i>Journal of Biological Chemistry</i> , 2001, 276, 29839-29845.	1.6	249
140	Reference Values for Plasma Dipeptidyl Peptidase IV Activity and Their Association with Other Laboratory Parameters. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 155-9.	1.4	57
141	Molecular characterization of dipeptidyl peptidase activity in serum. <i>FEBS Journal</i> , 2000, 267, 5608-5613.	0.2	242
142	Lowered Serum dipeptidyl peptidase IV activity in patients with anorexia and bulimia nervosa. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2000, 250, 86-92.	1.8	26
143	Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78 ¹² into a most efficient monocyte attractant and CCR1 agonist. <i>Blood</i> , 2000, 96, 1674-1680.	0.6	151
144	Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78 ¹² into a most efficient monocyte attractant and CCR1 agonist. <i>Blood</i> , 2000, 96, 1674-1680.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-Peptidase IV beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction. <i>Journal of Biological Chemistry</i> , 1999, 274, 3988-3993.	1.6	142
146	CD26, let it cut or cut it down. <i>Trends in Immunology</i> , 1999, 20, 367-375.	7.5	435
147	Lower Activity of Serum Peptidases in Abstinent Alcohol-Dependent Patients. <i>Alcohol</i> , 1999, 17, 1-6.	0.8	12
148	Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 1999, 79, 1042-1048.	2.9	47
149	Structure-Activity Relationship of Diaryl Phosphonate Esters as Potent Irreversible Dipeptidyl Peptidase IV Inhibitors. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1041-1052.	2.9	83
150	Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using high-performance liquid chromatography/electrospray mass spectrometry. , 1999, 34, 255-263.		13
151	The Effects of Psychological Stress on Leukocyte Subset Distribution in Humans: Evidence of Immune Activation. <i>Neuropsychobiology</i> , 1999, 39, 1-9.	0.9	115
152	CD26/DPP IV-mediated modulation of acute rejection. <i>Transplantation Proceedings</i> , 1999, 31, 873.	0.3	11
153	Specific inhibition of CD26/DPP IV enzymatic activity in allograft recipients: effects on humoral immunity. <i>Transplantation Proceedings</i> , 1999, 31, 778.	0.3	8
154	CD26-processed RANTES(3â€“68), but not intact RANTES, has potent anti-HIV-1 activity. <i>Antiviral Research</i> , 1998, 39, 175-187.	1.9	75
155	EFFECTS OF PSYCHOLOGICAL STRESS ON SERUM PROLYL ENDOPEPTIDASE AND DIPEPTIDYL PEPTIDASE IV ACTIVITY IN HUMANS: HIGHER SERUM PROLYL ENDOPEPTIDASE ACTIVITY IS RELATED TO STRESS-INDUCED ANXIETY. <i>Psychoneuroendocrinology</i> , 1998, 23, 485-495.	1.3	33
156	Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. <i>European Journal of Immunology</i> , 1998, 28, 1262-1271.	1.6	130
157	Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1±. <i>FEBS Letters</i> , 1998, 432, 73-76.	1.3	187
158	Functional Comparison of Two Human Monocyte Chemotactic Protein-2 Isoforms, Role of the Amino-Terminal Pyroglutamic Acid and Processing by CD26/Dipeptidyl Peptidase IVâ€. <i>Biochemistry</i> , 1998, 37, 12672-12680.	1.2	141
159	THE EFFECTS OF PSYCHOLOGICAL STRESS ON HUMANS: INCREASED PRODUCTION OF PRO-INFLAMMATORY CYTOKINES AND Th1-LIKE RESPONSE IN STRESS-INDUCED ANXIETY. <i>Cytokine</i> , 1998, 10, 313-318.	1.4	653
160	Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV. <i>Journal of Biological Chemistry</i> , 1998, 273, 7222-7227.	1.6	238
161	The influence of psychological stress on total serum protein and patterns obtained in serum protein electrophoresis. <i>Psychological Medicine</i> , 1998, 28, 301-309.	2.7	11
162	Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. <i>Psychological Medicine</i> , 1998, 28, 957-965.	2.7	32

#	ARTICLE	IF	CITATIONS
163	Immune and Clinical Correlates of Psychological Stress- Induced Production of Interferon-g and Interleukin-10 in Humans. , 1998, , .		1
164	In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (prodipine). <i>Biochemical Pharmacology</i> , 1997, 54, 173-179.	2.0	21
165	The effects of CD26/DPP IV-targeted therapy on acute allograft rejection. <i>Transplantation Proceedings</i> , 1997, 29, 1274-1275.	0.3	18
166	Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: Relationships with immune-inflammatory markers. <i>Psychoneuroendocrinology</i> , 1997, 22, 65-78.	1.3	49
167	Development and Evaluation of Peptide-Based Prolyl Oligopeptidase Inhibitors - Introduction of N-Benzyloxycarbonyl-Prolyl-3-Fluoropyrrolidine as a Lead in Inhibitor Design. <i>FEBS Journal</i> , 1997, 250, 177-183.	0.2	14
168	A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. <i>BBA - Proteins and Proteomics</i> , 1997, 1340, 215-226.	2.1	49
169	INHIBITION OF CD26/DIPEPTIDYL PEPTIDASE IV ACTIVITY IN VIVO PROLONGS CARDIAC ALLOGRAFT SURVIVAL IN RAT RECIPIENTS ^{1,2} . <i>Transplantation</i> , 1997, 63, 1495-1500.	0.5	97
170	Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1996, 1290, 76-82.	1.1	31
171	Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5). <i>Journal of Immunological Methods</i> , 1996, 189, 99-105.	0.6	97
172	Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. <i>Acta Psychiatrica Scandinavica</i> , 1996, 93, 1-8.	2.2	49
173	Distribution of Prolyl Oligopeptidase in Human Peripheral Tissues and Body Fluids. <i>Clinical Chemistry and Laboratory Medicine</i> , 1996, 34, 17-22.	1.4	48
174	The Purification, Characterization and Analysis of Primary and Secondary-Structure of Prolyl Oligopeptidase from Human Lymphocytes. Evidence that the Enzyme Belongs to the alpha/beta Hydrolase Fold Family. <i>FEBS Journal</i> , 1995, 233, 432-441.	0.2	46
175	Synthesis and evaluation of azaproline peptides as potential inhibitors of dipeptidyl peptidase IV and prolyl oligopeptidase. <i>International Journal of Peptide Research and Therapeutics</i> , 1995, 2, 198-202.	0.1	9
176	A new synthetic method for proline diphenyl phosphonates. <i>Tetrahedron Letters</i> , 1995, 36, 3755-3758.	0.7	17
177	Proline motifs in peptides and their biological processing. <i>FASEB Journal</i> , 1995, 9, 736-744.	0.2	400
178	Binding of adenosine deaminase to the lymphocyte surface via CD26. <i>European Journal of Immunology</i> , 1994, 24, 566-570.	1.6	86
179	Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidase. <i>Gene</i> , 1994, 149, 363-366.	1.0	42
180	Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster. <i>Immunobiology</i> , 1993, 188, 145-158.	0.8	24

#	ARTICLE	IF	CITATIONS
181	Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. <i>Psychiatry Research</i> , 1993, 49, 151-165.	1.7	145
182	Localization and characterization of aminopeptidase P in bovine adrenal medulla. <i>Neurochemistry International</i> , 1992, 21, 203-208.	1.9	6
183	Kinase activity in human platelets: Cleavage of the Arg1-Pro2 bond of bradykinin by aminopeptidase P. <i>Biochemical Pharmacology</i> , 1992, 44, 479-487.	2.0	34
184	Disturbances in dexamethasone suppression test and lower availability of 5-HT tryptophan and tyrosine in early puerperium and in women under contraceptive therapy. <i>Journal of Psychosomatic Research</i> , 1992, 36, 191-197.	1.2	39
185	Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes. <i>Clinica Chimica Acta</i> , 1992, 210, 23-34.	0.5	52
186	Aminopeptidase P and dipeptidyl peptidase IV activity in human leukocytes and in stimulated lymphocytes. <i>Clinica Chimica Acta</i> , 1991, 196, 87-96.	0.5	25
187	Exopeptidases in human platelets: an indication for proteolytic modulation of biologically active peptides. <i>Clinica Chimica Acta</i> , 1991, 195, 125-131.	0.5	18
188	Proteases and their inhibitors: today and tomorrow. <i>Biochimie</i> , 1991, 73, 121-126.	1.3	32
189	Decreased serum dipeptidyl peptidase IV activity in major depression. <i>Biological Psychiatry</i> , 1991, 30, 577-586.	0.7	61
190	Dipeptidyl peptidase IV in human lymphocytes: molecular properties. <i>Biochemical Society Transactions</i> , 1990, 18, 671-672.	1.6	2
191	Release of the carboxyterminal arginine from atriopeptin II by human plasma carboxypeptidase N. <i>Biochemical Society Transactions</i> , 1988, 16, 359-360.	1.6	5
192	Dipeptidyl peptidase IV activity in stimulated T lymphocytes. <i>Biochemical Society Transactions</i> , 1988, 16, 365-366.	1.6	7